Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

🩺 Protocol Summary

This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

Primary Research Facility: Chao Family Comprehensive Cancer Center, University of California Irvine (Orange, California)

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Allogeneic Hematopoietic Stem Cell Transplantation?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged between 18 Years and 70 Years?

🔍 Protocol Specified Age Range: 18 Years to 70 Years

Able to attend required clinic visits at Chao Family Comprehensive Cancer Center, University of California Irvine (Orange, California)?

🔍 Logistical Requirement: Site at Chao Family Comprehensive Cancer Center, University of California Irvine

📍 Primary Site Map

Site: Chao Family Comprehensive Cancer Center, University of California Irvine — Orange, California

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.